The latest update for Perspective Therapeutics comes with a trimmed Fair Value estimate, moving from US$12.29 per share to ...

Acumen Pharmaceuticals' lead Alzheimer's drug sabirnetug failed to show clinical efficacy in the ALTITUDE-AD trial. See why ...

Amgen has been posting strong financial results. In the second quarter, the company's revenue increased by 10% year over year ...

BENGALURU: Karnataka’s Information Technology and Biotechnology Minister Priyank Kharge has invited the state’s tech ...

As an IT salaryman, I spend my days tapping away at a keyboard and my nights staring at charts, tracking the waves of the ...

Cullinan Therapeutics (CGEM) is back in focus after regulators in the U.S. and Australia cleared a global Phase 1b/2a trial ...

Johns Hopkins researchers identified the mechanism by which gut bacteria toxin BFT causes colon cancer. Learn about the ...

Indiaspora warns that proposed US H-1B visa fee hikes and selection changes could disrupt tech and healthcare sectors, ...

The tests, created by rhinologist Dr. Henry Barham, measure bitter taste receptors that he believes may help predict how ...

Korea opened its one-month youth startup patent fast track to every field on Nov. 1, 2026. See who qualifies, the numbers and ...

NRX Pharmaceuticals Inc. faces heightened investor anxiety after adverse trial news, with stocks having been trading down by ...

Should you buy these stocks, too?